Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

ProMIS™ Neurosciences, Inc. (Nasdaq: PMN), is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company has offices in Toronto, Ontario, and Cambridge, Massachusetts.

Toronto, Canada Office


1920 Yonge Street
Suite 200
Toronto, ON M4S 3E2

Cambridge, MA U.S. Office


Cambridge Innovation Center
1 Broadway
Cambridge, MA 02142